within Pharmacolibrary.Drugs.ATC.J;

model J05AB13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 6.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.00108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Penciclovir is an antiviral drug belonging to the guanine analogue class, primarily used for the treatment of herpes simplex virus (HSV) infections, including cold sores (herpes labialis). It is available in topical form for external use, and is not typically administered systemically in clinical practice. Famciclovir, an oral prodrug of penciclovir, is approved for systemic treatment.</p><h4>Pharmacokinetics</h4><p>PK parameters reported in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Thomasy, SM, et al., &amp; Maggs, DJ (2012). Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. <i>American journal of veterinary research</i> 73(7) 1092–1099. DOI:<a href=&quot;https://doi.org/10.2460/ajvr.73.7.1092&quot;>10.2460/ajvr.73.7.1092</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22738064/&quot;>https://pubmed.ncbi.nlm.nih.gov/22738064</a></p></li><li><p>Gill, KS, &amp; Wood, MJ (1996). The clinical pharmacokinetics of famciclovir. <i>Clinical pharmacokinetics</i> 31(1) 1–8. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199631010-00001&quot;>10.2165/00003088-199631010-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8827396/&quot;>https://pubmed.ncbi.nlm.nih.gov/8827396</a></p></li><li><p>Fowles, SE, et al., &amp; Staniforth, D (1992). The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. <i>European journal of clinical pharmacology</i> 43(5) 513–516. DOI:<a href=&quot;https://doi.org/10.1007/BF02285093&quot;>10.1007/BF02285093</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1336464/&quot;>https://pubmed.ncbi.nlm.nih.gov/1336464</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AB13;
